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Abstract 
A series of five iron(III) complexes, namely [Fe(HL1)Cl2] (1), [Fe(HL
2)Cl2]·1.6H2O 
(2·1.6H2O), [Fe(HL
3)(MeOH)Cl2]·0.5H2O (3·0.5H2O), [Fe(HL
4)(MeOH)Cl2]·0.5H2O 
(4·0.5H2O) and [Fe(HL
4)(dmf)Cl2]·0.5Et2O·H2O (4´·0.5Et2O·H2O), where H2L
1 = L-
proline salicylaldehyde thiosemicarbazone (L-Pro-STSC), H2L
2 = pyrrolidine substituted 
L-Pro-STSC, H2L
3 = phenyl substituted L-Pro-STSC and H2L
4 = naphthyl substituted L-
Pro-STSC, has been synthesised. The two ligand precursors (H2L
3 and H2L
4) and iron 
complexes were characterised by elemental analysis, spectroscopic methods (UV-vis, 
IR and NMR), ESI mass spectrometry and single crystal X-ray crystallography (1‒3 and 
4’). Magnetic properties of the five-coordinate complex 2 and six-coordinate complex 4 
have been also investigated. The antiproliferative activity of the organic hybrids and 
their iron(III) complexes have been studied in vitro in five human and one murine cancer 
cell lines, as well as in human noncancerous fetal lung fibroblast cell line. According to 
structure-activity relationship, introduction of aromatic groups such as phenyl or 
naphthyl enhances the cytotoxic potency of the hybrids in the following order H2L
1< 
H2L
2< H2L
3< H2L
4. Coordination of the hybrids to iron(III) improves their antiproliferative 
activity in the majority of investigated cell lines. 
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Introduction 
Thiosemicarbazones (TSCs) as excellent metal chelators are a class of organic 
compounds with structural diversity1,2 and broad spectrum of pharmacological activities, 
such as antiproliferative, antiviral, antibacterial, antimalarial and antifungal.3 The 
research interest in TSCs as antiproliferative agents was aroused in 1950’s, when p-
aminobenzaldehyde thiosemicarbazone was found to inhibit virus multiplication, where 
the synthesis of nucleoproteins was required.4 Later on, by replacement of the 
benzaldehyde moiety with pyridine-2-carboxaldehyde one, two new compounds, 
namely, 5-hydroxy-2-formylpyridine thiosemicarbazone (5-HP)5,6 and 3-aminopyridine-2-
carboxaldehyde thiosemicarbazone (Triapine),7 were discovered to possess much 
higher anticancer activity in vitro and in vivo compared to 2-hydroxy-benzaldehyde 
thiosemicarbazones and promoted to clinical studies. The reason for this cytotoxicity 
enhancement is still unknown. Triapine was investigated in more than 20 clinical phase I 
and II trials as anticancer drug candidate, showing mixed results and considerable side 
effects.8 However, it still remains a prominent investigational TSC in fight against 
cancer. 
 
Two enzymes, namely ribonucleotide reductase (RNR)9 and topoisomerase II (topo II), 
which are responsible for DNA synthesis and (de)catenation of DNA-chain during 
transcription, as well as replication and repair are predominantly studied as targets in 
the underlying mechanisms of their antiproliferative activity. It is well known, that 
disturbance of the enzyme activity (RNR and/or topoII) indirectly leads to cell 
apoptosis.10 Other events such as mitochondrial disruption,11 inhibition of multidrug 
resistance protein,12 inhibition of epithelial-to-mesenchymal transition13 and inhibition of 
oncogenic signaling pathways14 are also attributed to anticancer activity of TSCs.  
 
Drug design strategies for the enhancement of TSCs cytotoxicity rely on the introduction 
of either bulky aliphatic and aromatic groups or a heteroatom in the TSC backbone, as 
well as on metal coordination.22,8,15,16,17,18  
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Quite recently, two other members of the TSC family, namely, di-2-pyriylketone 4-
cyclohexyl-4-methyl-3-thiosemicarbazone (DpC) and (E)-N´-(6,7-dihydroquinolin)-8(5H)-
ylidene)-4-(pyridine-2-yl)piperazine-1-carbothiohydrazide (COTI-2) have entered clinical 
studies, showing multi-target features,19,20 and rekindling the research interest in TSCs. 
 
Besides the good cytotoxicity and the selectivity for cancer cells, very often further 
anticancer investigations are prohibited because of low water solubility and high 
lipophilicity of TSCs. Finding an appropriate hydrophilicity/lipophilicity balance of a 
potent anticancer drug candidate is still a challenge.21  
 
Rapid tumour growth requires increasing amounts of essential metal ions (iron, copper, 
zinc). Their deficiency makes cancer cells more sensitive to chemotherapeutics 
compared to normal cells.1111,1414,22 Complexes of TSCs with essential transition metal 
ions do not always exhibit better in vitro cytotoxicity than metal-free TSCs 
alone.2,8,10,15,16,17,18 According to the previous studies, only few iron TSC complexes 
showed an improved cytotoxic effect upon coordination to iron.23,24 Although they can 
activate various pathways leading ultimately to cell apoptosis, their mechanism of 
inhibition of cell proliferation is still unknown. The formation of reactive oxygen species 
(ROS) which damage cellular processes and leads to cell apoptosis is a feature often 
attributed to anticancer activity of iron(III) complexes of TSCs.2,25 In addition, L-proline is 
distinct from other amino acids since it is only secondary amino acid. The metabolism of 
proline is different and takes place in the presence of special enzymes. It is 
accompanied by formation of signaling ROS for epigenetic reprogramming by 
oncogenes, and regulates redox homeostasis. These regulatory functions play an 
important role in apoptosis, autophagy and hypoxy in the presence of low oxygen levels 
typical for cancer.26 
 
Several years ago, we reported on the synthesis of 3-formyl-2-hydroxy-5-methylbenzyl)-
L-proline and 3-formyl-2-hydroxy-5-methylbenzyl)-D-proline (L-Pro-MSA and D-Pro-
MSA, respectively), which are closely related to monophyllidin (Figure 1), a naturally 
occurring alkaloid with antibacterial effect towards Enterococcus faecalis.27 By 
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condensation reactions with thiosemicarbazides new thiosemicarbazone-proline hybrids 
were synthesized, namely, L-Pro-STSC and D-Pro-STSC with improved water solubility 
and enhanced anticancer activity, particularly, upon the coordination to the metal.1818  
 
Figure 1. Line drawings of monophyllidin, L-Pro-MSA and L-Pro-STSC. 
 
These hybrid molecules (L-Pro-STSC and D-Pro-STSC) form mono-ligand complexes 
with iron(III/II), copper(II) and zinc(II) and, in addition, bis-ligand complexes with 
iron(III/II).1818 The metal-free hybrids showed only moderate cytotoxic potency towards 
colon cancer (SW480) and ovarian cancer (CH1) cell lines, while coordination to 
copper(II) markedly increased their cytotoxicity. The replacement of the phenolic moiety 
(in L-Pro-STSC) by pyridine (in 3-methyl-(S)-pyrrolidine-2-carboxylate-2-formylpyridine 
thiosemicarbazone, L-Pro-FTSC) does not significantly improve cytotoxic properties of 
the hybrids, most probably due to a further enhancement of the hydrophilic 
character.2121 The structural modifications at the terminal N atom of the TSC moiety in L-
Pro-STSC and coordination to essential metals had a beneficial impact on the 
cytotoxicity, while the changes on the proline moiety of the hybrids reduced 
antiproliferative activity.28 The results prompted us to extend the series of L-Pro-STSC 
conjugates by attachment of aromatic groups at terminal N atom of TSCs to increase 
their lipophilic character, and hopefully their cytotoxic potency. We anticipated that L-
Pro-STSC (H2L
1), Pyrr-L-Pro-STSC (H2L
2) and two conjugates namely, phenyl-L-Pro-
STSC (H2L
3) and 2-naphthyl-L-Pro-STSC (H2L
4) will form mono-ligand complexes with 
iron(III) providing better insight into (i) the role of iron coordination and its effect on 
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antiproliferative activity, (ii) the effect of aromatic groups at terminal N atom on 
antiproliferative activity of the conjugates as well as of their iron(III) complexes. 
Herein we report on the synthesis and characterisation of two N-monosubstituted L-Pro-
STSC conjugates (H2L
3 and H2L
4) and five iron(III) complexes (1‒4 and 4´) which have 
been prepared and isolated in the solid state (Figure 2) and characterised by elemental 
analysis, spectroscopic methods, magnetic susceptibility measurements, 
electrochemistry and X-ray diffraction.  
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Figure 2. Line drawings of the L-Pro-STSC hybrids and their iron(III) complexes studied 
in this work. Underlined numbers indicate complexes studied by X-ray diffraction. Co-
crystallised solvent molecules were omitted. 
 
In particular, coordination chemistry of the hybrids (namely, L-Pro-STSC (H2L
1), 
pyrrolidyl-L-Pro-STSC (H2L
2), phenyl-L-Pro-STSC (H2L
3) and 2-naphthyl-L-Pro-STSC 
(H2L
4)), the effects of iron(III) coordination and N-terminal substitution of TSC moiety on 
cytotoxicity in six human cancer cell lines, namely, cervical cancer cells (HeLa), 
melanoma cells (FemX), adenocarcinoma alveolar basal cells (A549), colon cancer 
cells (LS-174), breast cancer cells (MDA-MB-453), murine transformed endothelial cell 
line (MS1) and noncancerous fetal lung fibroblast (MRC-5) have been investigated and 
discussed.  
 
Results and discussion 
Synthesis and characterisation of the ligand precursors. The chiral proligands L-
Pro-STSC (H2L
1) and Pyrr-L-Pro-STSC (H2L
2) have been synthesised as described 
previously.1818,2828 The reaction of L-Pro-MSA with 4-phenyl-3-thiosemicarbazide in 
ethanol-water mixture and 4-(1-naphthyl)-3-thiosemicarbazide in ethanol afforded H2L
3 
and H2L
4 in 64 and 65% yield, respectively. ESI mass spectra of H2L
3 and H2L
4 
measured in negative ion mode showed characteristic peaks with m/z 411 and 461 
attributed to [M‒H]‒, while those measured in positive ion mode revealed peaks with 
m/z 413 and 485, respectively, assigned to [M+H]+ and [M+Na]+. The formation of 
proline-thiosemicarbazone hybrids H2L
3 and H2L
4 was also confirmed by one-
dimensional (1H and 13C) and two-dimensional (1H- 1H COSY, 1H- 13C HMBC and 
HSQC) NMR measurements (see experimental part and Figures S1–S14). 
Synthesis and characterisation of iron(III) complexes. Iron(III) complexes 1‒3 have 
been prepared by reaction of FeCl3·6H2O with the corresponding proligand (H2L
1, H2L
2 
or H2L
3) in methanol. A small excess of iron(III) salt (ca. 0.3 equiv) assured the 
formation of the mono-ligand complexes [Fe(HL1–3)Cl2]. Vapour diffusion of Et2O in 
methanolic solution of the complexes afforded X-ray diffraction quality crystals of 1‒3 in 
25, 33 and 61% yield, respectively. Complex 4 resulted from reaction of FeCl3·6H2O 
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with H2L
4 in ethanol/water mixture (1:1). Evapouration of the solvent under reduced 
pressure followed by dissolution of the residue in methanol and precipitation with Et2O 
gave rise to pure solid 4. By vapour diffusion of Et2O into the solution of 4, in dmf, single 
crystals of 4’ were obtained. 
All iron(III) complexes were characterised by elemental analysis, IR (Figures S15‒S19), 
UV‒vis, CD spectroscopy and ESI mass spectrometry. ESI mass spectra of iron(III) 
complexes in negative ion mode exhibited strong peaks with m/z 459, 514, 537 and 
586, respectively, attributed to [Fe(L1)Cl2]
−, [Fe(L2)Cl2]
−, [Fe(L3)Cl2]
− and [Fe(L4)Cl2]
−, 
respectively, while in positive ion mode peaks assigned to [Fe(H2L
1‒4)]+ were observed 
(see Experimental part). UV–vis spectra of 1‒4 in methanol and 4´ in dmf showed 
intraligand transitions and metal-to-ligand charge transfer bands between 250 and 600 
nm (Figure S20‒S24). In CD spectra of 1‒4 (Figure S25) the presence of enantiomeric 
excess was observed due to the chiral L-proline moiety in the complexes. The structures 
of the iron complexes in the solid state were established by single crystal X-ray 
diffraction. 
X-ray crystallography. The results of X-ray diffraction studies of 1, 
2·0.2CH3OH·0.125Et2O·0.063H2O, 3·0.5CH3OH and 4’·Et2O are shown in Figure 3 and 
4, respectively, with selected geometric parameters quoted in the legends. The 
compounds 1‒3 and 4´ crystallised in the noncentrosymmetric space groups P1, P3221, 
P21 and P212121, respectively, as pure enantiomers, as confirmed by the Flack 
parameters in Table 1. The asymmetric unit of 1 consists of four independent molecules 
of the iron(III) complex [Fe(HL1)Cl2], while that of 2·0.2CH3OH·0.125Et2O·0.063H2O of 
two crystallographically independent molecules of [Fe(HL2)Cl2] and co-crystallised 
solvent. 
The ligands in complexes 1 and 2 act as tridentate monoprotonated species (HL1)‒ and 
(HL2)‒ coordinating to iron(III) via the phenolato oxygen atom O1a, the nitrogen atom 
N1a and the thione sulfur S1a as shown for one crystallographically independent 
complex in Figure 3. The coordination polyhedron of iron(III) is close to square-
pyramidal ( is 0.12 and 0.15 in 1 and 2, respectively)29 and is completed by two 
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chlorido ligands, one in the basal plane, while another in the apical position. The proline 
moiety adopts the zwitterionic form and is not involved in coordination to iron(III). 
Protonation of N4a makes this atom in addition to C14a chiral. Both atoms adopt the 
same S configuration as observed recently in complexes of nickel(II), palladium(II) and 
copper(II) with the same type of proline-thiosemicarbazone hybrids.1818,2826 Opposite 
configurations of these two atoms are also well-documented in the literature.2121,30  
Figure 3. ORTEP views of 1 (left) and 2 (right) with atom labeling scheme; thermal 
ellipsoids were drawn at the 50% probability level. Selected bond distances (Å) and 
bond angles (°) in 1: Fe1a‒O1a 1.878(2), Fe1a‒N1a 2.193(2), Fe1a‒S1a 2.3585(9), 
Fe1a‒Cl1a 2.2245(8), Fe1a‒Cl2a 2.2616(8), C1a‒O1a 1.315(4), N1a‒N2a 1.387(3), 
N2a‒C8a 1.327(4), C8a‒S1a 1.707(3), C8a‒N3a 1.322(4); O1a‒Fe1a‒N1a 82.81(9), 
N1a‒Fe1a‒S1a 78.52(7); in 2: Fe1a‒O1a 1.899(4), Fe1a‒N1a 2.148(5), Fe1a‒S1a 
2.3769(17), Fe1a‒Cl1a 2.2332(18), Fe1a‒Cl2a 2.2473(19), C1a‒O1a 1.311(7), 
N1a‒N2a 1.383(7), N2a‒C8a 1.335(8), C8a‒S1a 1.726(7), C8a‒N3a 1.307(8); 
O1a‒Fe1a‒N1a 84.00(19), N1a‒Fe1a‒S1a 78.70(15). The molecules of solvent were 
omitted for clarity. 
The iron(III) atom comes out from the basal plane defined by donor atoms O1a, N1a, 
S1a and Cl2a towards Cl1a in 1 and 2 by 0.579 and 0.561 Ǻ, respectively.  
In complexes 3 and 4’ the ligands (HL3)‒ and (HL4)‒ are bound to iron(III) similarly. 
However, iron(III) in 3 and 4’ adopts a distorted octahedral coordination geometry with 
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one chlorido ligand and one molecule of solvent (methanol or dmf) in axial positions, 
and another chlorido ligand, along with three donor atoms of the corresponding 
tridentate ligand occupying the equatorial coordination places as shown in Figure 4. The 
increase of coordination number in 3 and 4’ is presumably due to the presence of 
electron-withdrawing substitutents at terminal thioamide nitrogen atom of 
thiosemicarbazide moiety in both these complexes, which decreases the electron 
density on iron atom. As a result the affinity for a sixth ligand (MeOH or dmf) increases. 
 
Figure 4. ORTEP view of 3 (left) and 4’ (right) with atom labeling scheme; thermal 
ellipsoids were drawn at the 50 and 30% probability level, respectively. Selected bond 
distances (Å) and bond angles (°) in 3: Fe1a‒O1a 1.896(2), Fe1a‒N1a 2.188(6), 
Fe1a‒S1a 2.431(2), Fe1a‒Cl1a 2.333(2), Fe1a‒Cl2a 2.303(2), Fe1a‒O4a 2.182(6),  
C1a‒O1a 1.307(9), N1a‒N2a 1.379(8), N2a‒C8a 1.338(9), C8a‒S1a 1.709(8), 
C8a‒N3a 1.333(9); O1a‒Fe1a‒N1a 86.7(2), N1a‒Fe1a‒S1a 78.85(16); in 4’: Fe‒O1 
1.923(2), Fe‒N1 2.178(3), Fe‒S1 2.4167(10), Fe‒Cl1 2.3633(11), Fe1‒Cl2 2.2915(11), 
Fe‒O4 2.101(4), C1‒O1 1.320(4), N1‒N2 1.380(4), N2‒C8 1.347(5), C8‒S1 1.701(4), 
C8‒N3 1.328(5); O1‒Fe‒N1 84.36(10), N1‒Fe‒S1 80.02(8). The molecules of solvent 
were omitted for clarity. 
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The Fe‒O, Fe‒N, Fe‒S and Fe‒Cl bond lengths in 3 and 4’ are markedly longer than 
those in a series of iron(III) complexes with 2-hydroxy-1-naphthaldehyde-
thiosemicarbazones reported recently.2424 This is probably due to the different 
coordination numbers in the two types of the compounds and reduced ligand-ligand 
repulsions in five-coordinate iron(III) complexes with 2-hydroxy-1-naphthaldehyde-
thiosemicarbazones.24  
 
The carboxylate group of the proline moiety is not coordinated to iron(III). Instead it is 
involved in formation of noncentrosymmetric dimeric associates via hydrogen bonds 
with nitrogen atoms of thiosemicarbazide fragment as shown in Figures S26‒S29. Five-
coordinate and six-coordinate complexes 1 and 3 form dimeric associates via the same 
set of hydrogen bonds. Even though the formation of dimeric associates is also found in 
the crystal structure of 2 (Figure S27), a dissimilar type of hydrogen bonding involved is 
due to the absence of terminal nitrogen as proton donor as was the case for 1 and 3. In 
4´ the presence of bulky naphthyl group at terminal nitrogen proton donor precludes the 
formation of dimeric associates. Instead the molecules of 4´ are building a 1D chain of 
H-bonded molecules with a two molecule portion shown in Figure S29. 
 
Solution speciation and UV–vis measurements for monitoring the stability of 
iron(III) complexes. The solution stability of the complexes 1–4 was investigated 
following the changes of UV–vis bands in the region of 200–700 nm in MeOH and in 
MeOH/H2O (1:1) solutions. UV–vis spectra of methanolic solutions of 1–4 did not show 
marked changes of the solutions even after 7 days of standing at room temperature 
(Figures S20–S24). The compounds 1 and 2 were stable in MeOH/H2O (1:1) over 15 h, 
while the complex 3 underwent changes after 30 min in MeOH/H2O (1:1) solution at 
room temperature. The formation of precipitate was observed after 15 h (Figures S30–
S32). These changes are partly due to the limited solubility of the complex 3 under the 
given conditions, although the spectral changes indicate some decomposition of the 
complex as well. The solution speciation of the iron(III) – H2L
1 system was determined 
in a 30% (w/w) dmso/H2O mixture in our recent work
1818 via pH-potentiometric and UV–
vis spectrophotometric titrations. Results revealed the formation of mono-ligand 
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complexes such as [Fe(HL1)]2+, [Fe(L1)]+, and bis-ligand complexes: [Fe(HL1)(L1)], 
[Fe(L1)2)]
– and [Fe(L1)2(OH)]
2–. The protonated iron(III) complexes containing (HL1)– are 
formed typically in the acidic pH range, and the stability of the bis-ligand complex 
[Fe(L1)2)]
– is very high. As a consequence complex 1 with the originally [Fe(HL1)]2+ 
composition most probably has a different stoichiometry after dissolution in the aqueous 
solution. pKa of this complex is 2.91.
1818 This indicates the complete deprotonation of 
the non-coordinating hydrazinic N2–H atom at pH > 4.5. This deprotonation is 
accompanied by significant spectral changes as shown in Figure S33. However, spectra 
remain practically unchanged at pH between ~6 and ~10 as a result of the formation of 
the [Fe(L1)2)]
– complex even at 1:1 metal-to-ligand ratio. (Notably these spectra are 
fairly similar to those recorded at 1:2 metal-to-ligand ratio at pH between 6.8 and 9.8).18 
On the basis of the reported stability constants concentration distribution curves were 
calculated for complex 1 (Figure 5), which suggest that the proligand is mostly bound in 
the bis-ligand complex [Fe(L1)2]
2+ at pH 7.4 in solution. It should be also noted that the 
stability of the iron(III) complexes is significantly higher than that of the iron(II) 
species.1818 
 
Figure 5. Concentration distribution curves for complex 1 in the pH range from 2 to 8 
calculated on the basis of stability constants taken from ref.18. [ccomplex 1 = 1.0×10
−3 
M;T= 298 K,I = 0.10 M (KCl) in 30% (w/w) dmso/H2O]. 
Similar complexation processes and stoichiometry of the complexes are assumed for 
the other three proligands H2L
2–H2L
4 as they coordinate in a similar manner, namely, 
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via the O, N, S‒ donor set, but most likely the stability of the complexes somewhat 
differs due to the presence of different substituents at terminal nitrogen atom of 
thiosemicarbazide moiety. The substituents at the N-terminal position are located quite 
close to the sulfur atom, which is involved in the coordination. The electron-donating 
methyl substituents have an unambiguous effect on the electron distribution in the 
thioamide moiety, thus on the coordination bond as well. In the case of the α-N-pyridyl 
thiosemicarbazones the increased stability of the iron(III/II) complexes by the N-terminal 
dimethylation is well documented in one of our previous papers.31 Based on the solution 
speciation data, the iron(III) complexes of salicylaldehyde (and α-N-pyridyl 
thiosemicarbazones) show a more favoured formation of bis-complexes over the mono 
species. As a consequence, at 1:1 metal-to-ligand ratio not only mono species are 
formed, but bis-complexes too. It results in the appearance of unbound iron(III) ions 
which tend to hydrolyze without the presence of other chelating agents. In the biological 
assays no precipitation occurred (or it was not visible) as the free iron(III) was most 
probably complexed by the components of the applied medium.   
 
Magnetic susceptibility measurements. The temperature dependence of the 
magnetic susceptibility (χMT) for complexes 2 and 4 was measured and a Curie plot is 
shown in Figure S34. At room temperature, the χMT product is equal to 4.25 mL
 K mol−1 
for 2 and 4.30 mL K mol−1 for 4. These values correspond well to the isolated high-spin 
iron(III) (S = 5/2)32 with isotropic g values 1.97 and 1.98 for 2 and 4, respectively. At low 
temperature a sharp decrease of χMT values is observed. Taking into account the 
mononuclear structure of 2 and 4 this behaviour is, presumably, due to the non-
negligible zero field splitting (ZFS)33 of iron(III), as well as to the presence of 
intermolecular interactions in 2 and 4. 
 
Electrochemistry. The electrochemical experiments on selected iron complexes were 
performed in MeCN/nBu4NPF6 solution at platinum working electrode at scan rate of 
100 mV s−1. As shown in Figure 6 the cathodic peak potential Epc of iron(III)/iron(II) 
redox couple is –0.23 V, –0.14 V, and –0.16 V vs. Fc+/Fc for 1–3, respectively. 
14 
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Figure 6. The cyclic voltammograms of 0.5 mM of 1 (black trace), 2 (blue trace) and 3 
(red trace) in MeCN/nBu4NPF6 at scan rate of 100 mV s
−1. 
 
The corresponding cyclic voltammograms showed one reduction peak with a strongly 
shifted reoxidation peak (peak-to-peak separation around 400 mV) exhibiting typical 
features of a slow electron process. The shape of the cyclic voltammograms in the 
reverse scan additionally indicates a weakly adsorbed reduction product, where a 
desorption characteristic for redissolution of presumably less soluble iron(II) species 
upon reoxidation to iron(III) state occurs. Therefore, for simulation of the corresponding 
cyclic voltammograms a small rate constant for the heterogeneous electron transfer was 
used (ks = 2.5 × 10
–4 cm s–1 for 1, ks = 1 × 10
–3 cm s–1 for 2 and ks = 5 × 10
–4 cm s–1 for 
3). As shown in Figure S35 a fairly good fit was achieved taking into account 
additionally the adsorption of the reduced species on the electrode surface 1 (max = 5 × 
10–6, 1 × 10–5 and 8 × 10–6 for 1–, 2– and 3– respectively) providing further evidence for 
adsorption processes. The simulation enabled us to determine the formal redox 
potentials for investigated iron complexes (E
o
’ = –0.67 V for 1, –0.65 V for 2 and –
0.65 V for 3, all vs. Fc+/Fc). These low redox potentials clearly occur within the 
biologically accessible window (−0.4 to +0.8 V vs. NHE) using the known E1/2 of 
ferrocene (+0.64 V) vs. Standard Hydrogen Electrode (SHE).34 These results are 
comparable with those reported for other iron(III)–TSC complexes.35,36 Such redox 
15 
 
active complexes are able to markedly increase the amount of reactive oxygen species 
(ROS) in cancer cells. Hydroxyl radicals in such systems can be obtained from Fenton 
reactions, where the iron cycles between the Fe(II) and Fe(III) oxidation states. 
 
Cytotoxicity. Cytotoxic potential of the hybrids H2L
1 ‒ H2L
4 and four iron(III) complexes 
1‒4 was investigated in five human and one murine cancer cell lines, namely HeLa, 
FemX, A549, LS-174, MDA-MB-453 and MS1, as well as in one noncancerous cell line 
MRC-5 by means of the colorimetric MTT-assay. The derivatives H2L
1 ‒ H2L
4 and their 
iron(III) complexes 1 ‒ 4 show IC50 values in the range from 14.7 to >300 μM (Table 1). 
The following structure-activity relationships were established: (i) the impact of 
substitution at terminal NH2 group of TSC moiety, (ii) impact of metal coordination of the 
hybrids and (iii) metal identity.   
 
Substitution at the terminal N atom of the TSC moiety. The favourable effect of 
terminal N atom substitution of the hybrid H2L
1 by pyrrolidinyl group in H2L
2, phenyl 
group in H2L
3 and naphthyl group in H2L
4 was observed by increase of the cytotoxic 
potency in the following order: H2L
1 < H2L
2 < H2L
3 < H2L
4 in all cancer cell lines except 
LS-174. In the latter, the rank order was H2L
1 < H2L
2 < H2L
4 < H2L
3. H2L
2 showed 
slightly better activity compared to H2L
1 in all cancer cell lines. The substitution with 
aromatic groups (hybrids H2L
3 and H2L
4) resulted in a 2- to more than 20-fold increase 
of cytotoxic potency of the hybrids in all cancer cell lines. Cancer cell lines FemX and 
MS1 were most sensitive to substitution of one H atom at terminal NH2 of TSC moiety 
by naphthyl group (hybrid H2L
4). IC50 values of 15 μM in FemX and 20 μM in MS1 cell 
lines, indicate ca. 20- and 15-fold increase of cytotoxicity compared to H2L
1.  
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Table 1. IC50 values after inhibition of cell growth by the hybrids H2L
1–H2L
4 and 
complexes 1–4 in six cancer cell lines (A549, FemX, HeLa, LS-174, MDA-MB-453 and 
MS1) and noncancerous cell line (MRC-5). 
IC50, μM (value ± SD)
[a]  
 A549 FemX HeLa LS-174 
MDA-
MB-453 
MS1 MRC-5 
H2L
1 >300[b] >300[b] >300[b] >300[b] >300[b] >300[b] >300[b] 
H2L
2 271±11 221±12 240±5 295±0 >300[b] 207±4 203±2 
H2L
3 141±4 31±2 146±7 48±3 >300[b] 125±8 211±9 
H2L
4 212±1 15±2 120±7 135±3 109±1 20±3 204±10 
1 51±7 53±3 61±3 91±6 39±1 44±3 26±2 
2 53±3 25±5 57±2 60±7 28±1 33±1 41±2 
3 72±1 54±2 52±4 87±3 40±1 39±3 52±3 
4 78±9 24±1 78±8 89±5 66±0 25±0 24±1 
cisplatin[c] 17±1[c] 11±1 8±2[c] 22±7 21±6 n.d. 30±3[c] 
[a] IC50 values were calculated as mean values obtained from three independent 
experiments after 48 h of cell exposure in the MTT assay. IC50 values are quoted with 
their standard deviations (SD). [b] The sign > indicates that IC50 value is not reached in 
the examined range of concentrations. [c] IC50 values for cisplatin were taken from ref. 
37.  
 
In the cell line MDA-MB-453 the positive effects of ligand substitution and metal 
coordination are also obvious. Introduction of naphthyl group increased the cytotoxicity, 
while coordination to iron enhanced it by a factor of 2. According to IC50 values, 
introduction of naphthyl group increased the cytotoxicity of H2L
1 by ca. 3 times, whereas 
coordination to iron improved the cytotoxicity of H2L
1 by ca. 8 times (complex 1). 
 
Notably, H2L
1 is mainly present in H2L (75%) and HL
– (25%) forms in aqueous solution 
at pH 7.4 based on its pKa values.
18 H2L has zwitter ionic structure containing negatively 
charged carboxylate and protonated proline nitrogen moieties, and HL– is formed by the 
deprotonation of the phenolic OH group. In all, these features strongly contribute to the 
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relatively high hydrophilicity of the compound H2L
1 (logD7.4 = –0.56).
18 Its derivatives 
H2L
3 and H2L
4 are most probably more lipophilic due to the presence of the phenyl and 
naphthyl groups, what is advantageous for the easier passage via the biological 
membranes resulting in the increased cytotoxicity. The drug delivery and activity of the 
iron complexes might be improved by attaching them to a prodrug carrier as recently 
published for a series of related iron complexes.24 All those iron complexes possess one 
tridendate Schiff-base ligand (modified just at terminal N-atom), one iron centre and two 
chloride ligands (as leaving groups).2424  
 
Metal coordination. Iron(III) complexes 1 and 2 showed an improved antiproliferative 
activity compared to their corresponding metal-free ligands in all cancer cell lines, which 
may be a consequence of the altered size, lipophilicity and charge upon complex 
formation. The strongest effect of iron coordination on cytotoxicity (ca. 9 fold increase) 
compared to the corresponding metal-free ligand, was observed for 2 in FemX cell line. 
On the other hand, coordination of the hybrids with aromatic substitutents (H2L
3 and 
H2L
4) to iron in 3 and 4 showed mixed results with increase of cytotoxic activity in HeLa, 
A549 and MDA-MB-453 cell lines and reduction of cytotoxic activity in MS1, LS-174 and 
FemX. According to IC50 values, an improved cytotoxic activity of iron(III) complexes 
towards investigated cell lines, could be attributed to their contribution to ROS 
generation, as previously reported,23,35 in addition to increasing of their lipophilicity by 
introduction of bulky aromatic groups. 
 
Metal identity. The coordination of H2L
2 to iron(III) increases the antiproliferative activity 
by a factor of 5 in A549 cell lines what is comparable with recently reported results for 
the same hybrid and its nickel(II), palladium(II) and copper(II) mono-ligand 
complexes.2826 The coordination to nickel(II) and palladium(II) led to a drop of cytotoxic 
potency of H2L
2, while coordination to copper increased it by a factor 9.5. Taking 
together, the following order of cytotoxic activity could be presented for nickel(II), 
palladium(II), copper(II) and iron(III) complexes of H2L
2 of 1:1 stoichiometry in A549 
cancer cell lines: Ni(II) < Pd(II) < H2L
2 < Fe(III) (5 fold) < Cu(II) (9.5 fold). 
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Selectivity. Comparing the IC50 values measured in the tested cancerous and the 
noncancerous cell lines it can be concluded that all compounds showed poor selectivity 
or no selectivity to cancer cell lines. The proligands H2L
3 and H2L
4, possess slightly 
better selectivity to cancer cells compared to their corresponding iron(III) complexes, 
where the selectivity is absent.  
Conclusions 
Two hybrids H2L
3 and H2L
4, and five iron(III) complexes 1‒4 and 4' were synthesised, 
characterised by spectroscopic, ESI-MS and magnetic susceptibility methods and their 
antiproliferative activity against six human and murine cancer cell lines and one normal 
cell line was studied. The substitution at the terminal NH2 group of the TSC moiety of the 
hybrids induces positive cytotoxic effect, which may be attributed to their 
hydrophilicity/lipophilicity balance.  
Iron(III) complexes were isolated in solid state and their structure was confirmed by X-
ray diffraction measurements, mass spectrometry and elemental analysis. Attachment 
of aromatic groups to terminal N atom of TSC moiety favours octahedral coordination 
geometry of central iron atom, while introduction of aliphatic groups induces square-
pyramidal coordination geometry, which is attributed to electron-withdrawing or electron-
donating effect of the substituents at the terminal N atom of TSC moiety of the hybrids, 
respectively. Thus, the hybrids H2L
1 and H2L
2 with iron(III) form square-pyramidal 
complexes [Fe(HL1)Cl2] (1) and [Fe(HL
2)Cl2]·1.6H2O (2), while H2L
3 and H2L
4 
octahedral complexes [Fe(HL3)(MeOH)Cl2]·0.5H2O (3) and 
[Fe(HL4)(dmf)Cl2]·0.5Et2O·H2O (4’). However, these differences observed in the solid 
state are not characteristic for their behaviour in solution. Instead, favoured formation of 
bis-ligand iron(III) complexes is observed, in addition to mono-ligand complexes, at 
physiological pH.  
The substitution at the terminal NH2 group of TSC moiety of H2L
1 by pyrrolydinyl, 
phenyl, and naphthyl group enhances the antiproliferative activity of all hybrids in all 
investigated cancer cell lines with exception of colon cancer cell line (LS-174) where the 
cytotoxicity follows the order H2L
1 < H2L
2 < H2L
4< H2L
3. Iron(III) complexes 1–4 showed 
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better cytotoxic potency compared to their corresponding hybrids with exception of 
complex 3 in LS-174 cell line, complex 4 in MS1 cell line and complexes 3 and 4 in 
FemX, where they showed reduced cytotoxicity compared to their parent hybrids. On 
the other hand, neither hybrids nor complexes displayed significant selectivity toward 
cancerous cells over normal cells. In general, structural modification at terminal N atom 
of TSC moiety of the hybrids, especially by introducing aromatic groups, has significant 
impact on cytotoxicity. Metal coordination causes beneficial effects on cytotoxic activity, 
particularly in the case of essential transition metals (iron and copper). Metal identity 
affects the cytotoxic potency of the hybrids in agreement to our previous work in such a 
manner, that essential metals (iron and copper) improve cytotoxicity of the metal-free 
ligands, while other transition metals (Ni and Pd) reduce it. 
 
Experimental section 
Chemicals. All reagents were used as purchased from commercial suppliers. 4-Phenyl-
3-thiosemicarbazide and 1-isothiocyanatonaphthalene were purchased from Sigma 
Aldrich, L–proline from Alfa Aesar and FeCl3·6H2O from Riedel-de-Haën. 4-(1-
Naphthyl)-3-thiosemicarbazide was synthesised as described in the literature with 30% 
yield.38 
 
Synthesis of proligands 
The synthesis of H2L
1·1.5H2O was previously reported.
1818 2-Hydoxy-3-methyl-(S)-
pyrrolidine-2-carboxylate-5-methylbenzaldehyde (L-Pro-MSA) was prepared in 34% 
yield, starting from L–proline instead of methyl L–proline ester hydrochloride. The 
reaction product was purified by column chromatography using MeOH/CHCl3 (1:25) as 
eluent. H2L
2·2H2O was synthesised by following a previously published procedure.
2826  
 
H2L
3·2H2O. To a solution of L-Pro-MSA (740 mg, 2.82 mmol) in ethanol (5 mL) under 
stirring was added a solution of 4-phenyl-3-thiosemicarbazide (470 mg, 2.82 mmol) in 
water (5 mL). The reaction mixture was refluxed at 85 °C for 30 min and then cooled to 
room temperature and allowed to stand at 5 °C overnight. The precipitate was filtered 
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off, washed with cold EtOH/H2O (1:1) and dried in vacuo. Yield: 0.70 g, 64.0%. Anal. 
Calc. for C21H24N4O3S·2H2O (Mr 448.54): C 56.29, H 6.30, N 12.49, S 7.15; Found: C 
56.45, H 5.87, N 12.62, S 7.18. 1H NMR (500 MHz, (CD3)2SO, 25 °C): δ 11.82 (s, 1H, 
C=N–NH), 11.62 (s, 1H, CPh–OH), 10.03 (s, 1H, HN–CPh), 8.51 (s, 1H, HC=N), 7.88 (s, 
1H, C6H), 7.58 (d, 2H J = 7.7 Hz, C14H), 7.38 (t, 2H, J = 7.7 Hz, C15H), 7.22 (t, 2H, J = 
7.7 Hz, C16H) 6.98 (s, 1H, C4H), 4.16 (d, 1H, J = 13.33 Hz, CH2), 3.52 (d, 1H, J = 13.33 
Hz, CH2 peak partial overlapped with DHO proton signal), 2.91 (br. s, 1H, proline), 2.43 
(br. s, 1H, proline), 2.29–2.19 (m, 1H, proline), 2.23 (s, 3H, CH3), 1.93–1.80 (m, 2H, 
proline), 1.77–1.67 (m, 1H, proline). 13C{1H} NMR (126 MHz, (CD3)2SO, 25 °C): δ 
178.23 (C=S),  174.96 (CO2
-), 154.82 (CPh–OH), 140.23 (HC=N), 136.66 (C
13) 
134.18(CAr), 132.14(C4), 128.52 (C15), 127.79(C5), 126.47(C14+6), 126.49 (C6), 123.51 
(C3), 120.41 (C1), 65.63 (CH, proline), 56.41 (CH2(8)), 53.08 (CH2, proline), 29.46 (CH2, 
proline), 23.47 (CH2, proline), 20.55 (C
7H3).  ESI-MS in MeOH (positive): m/z 413 ([H2L
3 
+ H]+). ESI-MS in MeOH (negative): m/z 411 ([HL3]‒). UV–vis in MeOH, λ, nm (ε, 
M‒1cm‒1) 219 (19 891) 340 (19859) 310 (18500). IR (ATR, selected bands, νmax, cm
‒1) 
3611, 3440, 3258, 3208, 2986, 2859, 2322, 1618, 1549, 1471, 1386, 1314, 1265, 1223, 
1156, 1050, 757, 706.    
 
H2L
4·2H2O. To a solution of L-Pro-MSA (0.72 g, 2.74 mmol) in ethanol (20 mL) a 
solution of N-(naphthalen-1-yl)hydrazinecarbothioamide (0.59 g, 2.74 mmol) in ethanol 
(5 mL) was added. The reaction mixture was refluxed at 85 °C for 30 min. The solvent 
was evapourated under reduced pressure and the remaining solution (3 mL) was 
allowed to stand at 5 °C overnight. The precipitate was filtered off, washed with cold 
ethanol and dried in vacuo. Yield: 1.26 g, 65.0%. Anal. Calc. for C25H26N4O3S·2H2O (Mr 
498.60): C 60.22, H 6.06, N 11.24, S 6.43; Found: C 60.58, H 5.76, N 11.13, S 6.35. 1H 
NMR (500 MHz, (CD3)2SO, 25 °C) δ 11.92 (s, 1H, C=N-NH), 11.53 (s, 1H, CPh–OH), 
10.31 (s, 1H, HN–CPh), 8.57 (s, 1H, HC=N), 8.00-7.87 (m, 7H Ar), 7.94 (s, 1H, C
6H), 
6.97 (s, 1H, C4H), 4.17(d, 1H, J = 13.36 Hz, CH2), 3.49 (d, 1H, J = 13.36 Hz, CH2  peak 
overlapped with DHO proton signal), 3.37 (m, 1H, proline peak overlapped with DHO 
proton signal), 2.94–2.88 (m, 1H, proline), 2.55–2.35 (m, 1H, proline), 2.25–2.15 (m, 1H, 
proline), 2.20 (s, 3H, CH3), 1.95–1.80 (m, 2H, proline), 1.75–1.65 (m, 1H, proline), 
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13C{1H} NMR (126 MHz, (CD3)2SO, 25 °C) δ 178.07 (C=S), 175.10 (CO2
-), 154.82 (CPh–
OH), 139.99 (HC=N), 136.33(CAr), 134.18(CAr), 132.00(C4), 131.20 (CAr), 127.72(CAr), 
127.01(C5), 126.49 (CAr), 125.92 (CAr), 123.94 (CAr), 123.55 (C3), 120.57 (C1), 65.66 
(CH, proline), 56.46 (CH2(8)), 53.05 (CH2, proline), 29.48 (CH2, proline), 23.47 (CH2, 
proline), 20.54 (C7H3). ESI-MS in MeOH (positive): m/z 485 ([H2L
4 + Na]+). ESI-MS in 
MeOH (negative): m/z 461 ([H2L
4]‒). UV–vis in MeOH, λ, nm (ε, M‒1cm‒1) 222 (46523) 
340 (18611) 306 (17440). IR (ATR, selected bands, νmax, cm
‒1) 3612, 3431, 3223, 3018, 
2874, 2321, 1622, 1543, 1468, 1390, 1310, 1272, 1159, 1050, 1008, 975, 893, 859, 
776, 730, 701. 
 
Synthesis of iron(III) complexes 
[Fe(HL1)Cl2] (1). To a solution of H2L
1·1.5H2O
 (0.05 g, 0.14 mmol) in methanol (55 mL) 
under stirring, a solution of FeCl3·6H2O (0.05 g, 0.18 mmol) in methanol (2 mL) was 
added, and the reaction mixture was refluxed for 1.5 h. After cooling to room 
temperature the solvent was evapourated under reduced pressure to ca. 5 – 10 mL. X-
ray diffraction quality crystals were obtained by vapour diffusion of diethyl ether into the 
concentrated reaction mixture. These were washed with diethyl ether (5 mL) and dried 
in vacuo overnight. Yield: 0.02 g, 25.0%. Anal. Calc. for C15H19Cl2FeN4O3S (Mr 462.15): 
C 38.98, H 4.14, N 12.12, S 6.94; Found: C 39.20, H 4.19, N 12.24, S 6.73. ESI-MS in 
MeOH (negative): m/z 459 ([Fe(L1)Cl2]
‒). UV–vis in MeOH, λ, nm (ε, M‒1cm‒1) 623 (562), 
359 (7167), 289 (11433), 252 (12963), 218 (12520). IR (ATR, selected bands, νmax, 
cm‒1) 3368, 3294, 3065, 2979, 2915, 2731, 2693, 1643, 1554, 1398, 1305, 1169, 1049.   
 
[Fe(HL2)Cl2]·1.6H2O (2·1.6H2O). To a solution of H2L
2·2H2O (0.24 g, 0.56 mmol) in 
methanol (70 mL) a solution of FeCl3· 6H2O (0.21 g, 0.78 mmol) in methanol (6 mL) was 
added. The reaction mixture was stirred at room temperature for 1 h. A green solution 
was evapourated under reduced pressure to ca. 10 mL. Crystals of X-ray diffraction 
quality were obtained after ca. 7 days by vapour diffusion of diethyl ether into the 
concentrated reaction mixture. These were filtered off, washed with diethyl ether (20 
mL) and dried in vacuo overnight. Yield: 0.10 g, 32.8%. Anal. Calc. for 
C19H25Cl2FeN4O3S·1.6H2O (Mr 545.07): C 41.87, H 5.21, N 10.28, S 5.88; Found: C 
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41.80, H 4.92, N 9.93, S 5.71. ESI-MS in MeOH (negative): m/z 514 ([Fe(L2)Cl2]
‒). ESI-
MS in MeOH (positive): m/z 444 ([Fe(L2)]+), 480 ([Fe(HL2)Cl]+).  UV–vis in MeOH, λ, nm 
(ε, M‒1cm‒1) 621 (840), 474 sh, 366 (9853), 290 (18981), 267 (16253), 223 (17484). IR 
(ATR, selected bands, νmax, cm
‒1) 2973, 2878, 2836, 1724, 1583, 1488, 1445, 1360, 
1324, 1233, 1188, 1106, 1041, 993.  
 
[Fe(HL3)(MeOH)Cl2]·0.5H2O (3·0.5H2O). To a solution of H2L
3·2H2O
 (0.14 g, 0.33 
mmol) in methanol (70 mL) a solution of FeCl3· 6H2O (0.12 g, 0.43 mmol) in methanol (6 
mL) was added. The reaction mixture was stirred at room temperature for 2 h. The dark 
brown solution was evapourated under reduced pressure to ca. 10 mL. The crystalline 
solid was obtained after ca. 10 days by vapour diffusion of diethyl ether (Et2O) into the 
methanolic solution of the complex. The product was filtered off, washed with diethyl 
ether (10 mL) and dried in vacuo. Yield: 0.12 g, 61.0%. Anal. Calc. for 
C22H27Cl2FeN4O4S·0.5H2O (Mr 579.30): C 45.61, H 4.87, N 9.67, S 5.54; Found: C 
45.56, H 4.74, N 9.95, S 5.60. ESI-MS in MeOH (positive): m/z 466 ([Fe(L3)]+), 502 
([Fe(HL3)Cl]+), 538 ([Fe(H2L
3)Cl2 + H]
+). ESI-MS in MeOH (negative): m/z 537 
([Fe(L3)Cl2]
‒). UV–vis in MeOH, λ, nm (ε, M‒1cm‒1) 547 (1577), 489 (1848), 373 (12522), 
316 (14178), 293 sh, 260 sh, 230 (18771), 203 (18908). IR (ATR, selected bands, νmax, 
cm‒1) 3650, 2875, 1632, 1587, 1556, 1492, 1449, 1408, 1345, 1169, 1131, 1059, 1002, 
961.  
 
[Fe(HL4)(MeOH)Cl2]·0.5H2O (4·0.5H2O). To a solution of H2L
4·2H2O (0.10 g; 2.01 
mmol) in ethanol/water (3:2) (75 mL) a solution of FeCl3·6H2O (0.067 g, 2.48 mmol) in 
ethanol (5 mL) was added. The reaction mixture was stirred at room temperature 
overnight. The solvent was removed under reduced pressure and residue was dissolved 
in methanol (5 mL). After addition of Et2O (50 mL) the precipitate was filtered off, 
washed with Et2O (10 mL) and dried in vacuo overnight. Yield: 0.076 g, 59.4%. Anal. 
Calc. for C26H29Cl2FeN4O4S·0.5H2O (Mr 629.36): C 49.62, H 4.80, N 8.90, S 5.09; 
Found: C 49.50, H 4.49, N 8.81, S 4.94. ESI-MS in MeOH (positive): m/z 516 ([Fe(L4)]+). 
ESI-MS in MeOH (negative): m/z 586 ([Fe(L4)Cl2]
‒). UV–vis in MeOH, λ, nm (ε, M‒1cm‒1) 
23 
 
551 (1377), 358 (13871), 293 (16636), 249 sh. IR (ATR, selected bands, νmax, cm
‒1): 
3655, 2967, 2920, 1730, 1560, 1447, 1397, 1319, 1265, 1232, 1169, 1070, 1009, 924. 
 
[Fe(HL4)(dmf)Cl2]·0.5Et2O·H2O (4´·0.5Et2O·H2O). Complex 4 (7 mg) was dissolved in 
dimethylformamide (dmf) (0.6 mL). Vapour diffusion of Et2O into dmf solution of 4 
yielded X-ray diffraction quality crystals of 4´. Yield: 5.5 mg, 75.8%. Anal. Calc. for 
C28H32Cl2FeN5O4S·0.5Et2O·H2O (Mr 716.48): C 50.29, H 5.49, N 9.77, S 4.48; Found: C 
50.04, H 5.12, N 9.82, S 4.20. ESI-MS in MeOH (positive): m/z 516 ([Fe(L4)]+), 589 
([Fe(HL4)Cl2 + H]
+). ESI-MS in MeOH (negative): m/z 586 ([Fe(L4)Cl2]
‒), 550 
([Fe(HL4)Cl]‒), 459 (HL‒)). UV–vis in dmf, λ, nm (ε, M‒1cm‒1) 548 sh, 368 (12066), 307 
(13043). IR (ATR, selected bands, νmax, cm
‒1): 3060, 2966, 2926, 2858, 2654, 2326, 
1987, 1672, 1638, 1593, 1565, 1459, 1384, 1322, 1259, 1227, 1171, 1117, 1067, 1007, 
971, 875, 828, 771, 679, 605.  
 
Crystallographic structure determination. X-ray diffraction measurements of the 
complexes 1–3 were performed on Bruker D8 Venture (or Bruker X8 APEXII CCD) and 
of the complex 4' on STOE StadiVari diffractometer (detector Dectris Pilatus 300K, 
microfocus source Incoatec IμS Cu (Cu-Kα, λ = 1.54184 Å) at 100K). Bruker 
diffractometer was equipped with an Oxford Cryosystem nitrogen gas open-flow cooler 
and Stoe StadiVari with a nitrogen gas open-flow Cobra from Oxford Cryosystem. The 
software programs used for structure solution were SHELXS-9739 and X-Area STOE,40 
for structure refinement SHELXL-973936 and XD2006, respectively and for molecular 
diagrams ORTEP-3.41 CCDC 1557747–1557750. 
 
Physical measurements. Elemental analysis of all compounds was performed on a 
Perkin Elmer 2400 CHN Elemental Analyser (Perkin Elmer, Waltam, MA) at the 
Microanalytical Laboratory of the University of Vienna. Microanalytical data are within 
±0.4% of the calculated values. Electrospray ionisation mass spectrometry 
measurements were carried out on a Bruker Esquire 3000 instrument (Bruker Daltonic, 
Bremen, Germany) at Mass Sprectrometry Centre of the Faculty of Chemistry 
(University of Vienna). UV-vis spectra were measured on a Perkin-Elmer Lambda 650 
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spectrophotometer. The samples were prepared by dissolving the compounds in MeOH, 
dmf or solvent mixture MeOH/H2O 1:1 before measurement (900–210 nm). Infrared 
spectra were recorded on Perkin-Elmer FT–IR 2000 instrument (400–400 cm‒1) using 
ATR unit or Bruker Vertex 70 FT–IR spectrometer. NMR spectra were acquired on a 
Bruker Avance III 500 MHz FT–NMR spectrometer by using as a solvent (CD3)2SO. 
Magnetic measurements were carried out on microcrystalline samples 2 and 4 with a 
Quantum Design SQUID magnetometer (MPMS-XL) at 0.1 T in the temperature range 
2–300 K. Data were corrected for the contribution of the sample holder and 
diamagnetism of the samples estimated from Pascal’s constants.42 
 
Electrochemistry measurements. For cyclic voltammetry experiments commercially 
available acetonitrile (MeCN) Secco Solv (dried, max. 0.005% H2O) from Merck, and 
ferrocene (Fc) purchased from Sigma Aldrich were used without further purification. 
Tetrabutylammonium hexafluorophosphate (nBu4NPF6) of purissimum quality (Fluka) 
was dried under reduced pressure at 70 °C for 24 h. Cyclic voltammograms of the 
complexes in MeCN (1 mM) containing 0.1 M nBu4NPF6 as the supporting electrolyte 
were measured using a one-compartment electrochemical cell with platinum wires as 
the working and counter electrodes and a silver wire as the pseudoreference electrode. 
All electrochemical measurements were performed under nitrogen atmosphere. Cyclic 
voltammograms were measured using a HEKA PG 390 potentiostat at room 
temperature. DigiElch Professional software from Gamry Instruments (USA), version 
Digielch8, was used for digital simulations of cyclic voltammograms 
 
Cytotoxicity assay  
Cell lines and culture conditions. Human cervical carcinoma (HeLa), human 
melanoma (FemX), human alveolar basal adenocarcinoma (A549), human breast 
cancer (MDA-MB-453), colon cancer cell line (LS-174), murine transformed endothelial 
cell line (MS1) and normal lung fetal fibroblast cell line (MRC-5) were maintained as 
monolayer culture in the Roswell Park Memorial Institute (RPMI) 1640 nutrient medium 
(Sigma Chemicals Co, USA). RPMI 1640 nutrient medium was prepared in sterile 
ionised water, supplemented with penicilin (192 IU mL–1), streptomycin (200 mg mL–1), 
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4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES) (25 mM), L-glutamine 
(3 mM) and 10% of heat-inactivated fetal calf serum (FCS; pH 7.2). The cells were 
grown at 37 °C in 5% CO2 and humidified in air atmosphere, by twice weekly 
subculture. 
  
MTT–assay. Antiproliferative activity of the compounds was determined using 3-(4,5-
dimethylthiazol-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma Aldrich) assay.43 Cells 
were seeded into 96-well cell culture plates (Thermo Scientific Nunc) in an appropriate 
density for each cell line. After 24 h of growth, cells were exposed to the serial dilutions 
of the tested compounds. The compounds were dissolved in minimum amount of 
dimethyl sulfoxide (dmso) and afterwards diluted with nutrient medium to desired final 
concentrations (in the range up to 300 µM). The amount of dmso in prepared solutions 
was ≤ 1%. Each concentration was tested in triplicate. After incubation period of 48 h, 
20 µL of MTT solutions (5 mg mL–1 in phosphate buffer solution, pH 7.2) were added to 
each well. Samples were incubated at 37 °C with 5% CO2 in a humidified atmosphere 
for 4 h. Formazan crystals were dissolved in 100 µM of 10% sodium dodecyl sulfate 
(SDS). Absorbance values were recorded after 24 h, on an ELISA reader 
(ThermoLabsystem Multiskan EX 200–240 V) at the wavelength of 570 nm. The IC50 
values, defined as the concentrations of the compound causing 50% cell growth 
inhibition, were estimated from the dose-response curves. 
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Table 1. Crystal data and details of data collection for iron(III) complexes.  
Compound 1 2·0.2CH3OH·0.125Et2O·0.063H2O 3·0.5CH3OH 4´·Et2O 
empirical formula  C15H19Cl2FeN4O3
S 
C19.7H27.18Cl2FeN4O3.39S C22.5H29Cl2FeN4O4.5
S 
C32H42Cl2FeN5O5S 
Fw 462.15 533.04 586.30 735.51 
space group P1 P3221 P21 P212121 
a [Å] 11.7228(4) 15.2992(7) 10.0939(3) 15.2295(3) 
b [Å] 13.1340(5) 15.2992(7) 19.8953(6) 13.2442(3) 
c [Å] 14.2125(8) 39.998(2) 12.8165(4) 17.1575(3) 
 [°] 106.120(2)    
 [°] 97.415(2)  101.140(2)  
 [°] 113.163(2)    
V [Å3] 1861.10(14) 8107.9(7) 2525.33(13) 3460.71(12) 
Z 4 12 4 4 
 [Å] 0.71073 0.71073 0.71073 1.54186 
calcd [g cm
-3] 1.649 1.310 1.704 1.412 
crystal size [mm] 0.20  0.16  0.16 0.40  0.23  0.15 0.08  0.01  0.01  0.22  0.05  0.04 
T [K] 120(2) 100(2) 100(2) 100(2) 
 [mm-1] 1.233 0.860 7.849 5.865 
R1
[a] 0.0235 0.0609 0.0614 0.0485 
wR2
[b] 0.0629 0.1731 0.1549 0.1364 
Flack parameter ‒0.002(8) 0.04(3) −0.001(7) ‒0.011(5) 
GOF[c] 1.020 1.177 1.003 1.000 
a R1 = ||Fo|  |Fc||/|Fo|. 
b wR2 = {[w(Fo
2  Fc
2)2]/[w(Fo
2)2]}1/2. c GOF = {[w(Fo
2  Fc
2)2]/(n  p)}1/2, where n is the 
number of reflections and p is the total number of parameters refined.  
 
27 
 
Acknowledgements 
This study was financially supported by the Austrian Science Fund (project number 
P28223-N34), Research and Development Agency of the Slovak Republic under the 
contracts No. APVV-15-0079 and APVV-15-0053, Scientific Grant Agency of the Slovak 
Republic (VEGA Project 1/0871/16) and Slovak University of Technology in Bratislava 
(Young Researcher Grant, M. Milunović, PhD). This work was also supported by 
Ministry of Education, Science, Research and Sport of the Slovak Republic within the 
Research and Development Operational Program for the project “University Science 
Park of STU Bratislava”, ITMS 26240220084, co-funded by the European Regional 
Development Fund. 
Author Information 
Corresponding Authors 
E-mail: miljan.milunovic@univie.ac.at; vladimir.arion@univie.ac.at  
Notes 
The authors declare no competing financial interest. 
References  
                                                          
[1] a) D. X. West, S. B. Padhye, P. B. Sonawane, Struct. Bonding 1991, 76, 1-50; b) T. 
S. Lobana, R. Sharma, G. Bawa, S Khanna, Coord. Chem. Rev. 2009, 253, 977-1055; 
c) T. S. Lobana, RSC Adv. 2015, 5, 37231-37274. 
[2] Y. Yu, D. S. Kalinowski, Z. Kovacevic, A. R. Siafakas, P. J. Jansson, C. Stefani, D. 
B. Lovejoy, P. C. Sharpe, P. V. Bernhardt, D. R. Richardson, J. Med. Chem. 2009, 52, 
5271-5294. 
[3] H. Beraldo, D. Gambino, Mini Rev. Med. Chem. 2004, 4, 31-39. 
[4] D. Hamre, J. Bernstein, R. Donvick., Proc. Soc. Exper. Biol. & Med. 1950, 73, 275-
278. 
[5] R. C. DeConti, B. R. Toftness, K. C. Agrawal, R. Tomchick, J. A. R. Mead, J. R. 
Bertino, A. C. Sartorelli, W. A. Creasey, Cancer Res. 1972, 32, 1455-1462. 
[6] I. H. Krakoff, E. Etcubanas, C. Tan. K. Mayer, V. Bethune, J. H. Burchenal, Cancer 
Chemother. Rep. 1974, 58, 207-212. 
[7] M. -C. Liu, T. -S. Lin, A. C. Sartorelli, J. Med. Chem. 1992, 35, 3672-3677. 
28 
 
                                                                                                                                                                                           
[8] C. Stefani, P. J. Jansson, E. Gutierrez, P. V. Bernhardt and D. Richardson, J. Med. 
Chem. 2013, 56, 357-370. (ref. therein) 
[9] P. Nordlund, P. Reichard, Annu. Rev. Biochem. 2006, 75, 681-706. 
[10] B. M. Zeglis, V. Divilov, J. S. Lewis, J. Med. Chem. 2011, 54, 2391-2398. 
[11] J. Yuan, D. B. Lovejoy, D. R. Richardson, Blood 2004, 104, 1450-1458. 
[12] C. P. Wu, S. Shukla, A. M. Calcagno, M. D. Hall, M. M. Gottesman, S. V. 
Ambudkar, Mol. Cancer. Ther. 2007, 6, 3287-3296. 
[13] S. Sahni, D.-H. Bae, D. J. R. Lane, Z. Kovacevic, D. S. Kalinowski, P. J. Jansson, 
D. R. Richardson, J. Biol. Chem. 2014, 289, 9692-9709. 
[14] P. J. Jansson, D. S. Kalinowski, D. J. Lane, Z. Kovacevic, N. A. Seebacher, L. 
Fouani, S. Sahni, A. M. Merlot, D. R. Richardson, Pharmacol. Res. 2015, 100, 255-260. 
[15] I. Đilovic, M. Rubcic, V. Vrdoljak, S. K. Pavelic,  M. Kralj, I. Piantanida, M. Cindric, 
Bioorg. Med. Chem. 2008, 16, 5189-5198. 
[16] C. R. Kowol, R. Trondl, P. Heffeter, V. B. Arion, M. A. Jakupec, A. Roller, M. 
Galanski, W. Berger, B. K. Keppler, J. Med. Chem. 2009, 52, 5032-5043. 
[17] C. Stefani, G. Punnia-Moorthy, D. B. Lovejoy, P. J. Jansson, D. S. Kalinowski, P.C. 
Sharpe, P. V. Bernhardt, D. Richardson, J. Med. Chem. 2011, 54, 6936-6948. 
[18] M. N. M. Milunovic, E. A. Enyedy, N. V. Nagy, T. Kiss, R. Trondl, M. A. Jakupec, B. 
K. Keppler, R. Krachler, G. Novitchi, V. B. Arion, Inorg. Chem. 2012, 51, 9309-9321. 
[19] https://clinicaltrials.gov/ct2/show/NCT02433626. Accessed on 24/06/2017. 
[20] K. Y. Salim, S. M. Vareki, W. R. Danter, J. Koropatnick, Oncotarget 2016, 7, 41363-
41379. 
[21] F. Bacher, E. A. Enyedy, N. V. Nagy, A. Rockenbauer, G. M. Bognar, R. Trondl, M. 
S. Novak, E. Klapproth, T. Kiss, V. B. Arion, Inorg. Chem. 2013, 52, 8895-8908. 
[22] S. Ishida, P. Andreux, C. Poitry-Yamate, J. Auwerx, D. Hanahan, Proc. Natl. Acad. 
Sci. U.S.A. 2013, 110, 19507-19512. 
[23] Y. Gou, J. Wang, S. Chen, Z. Zhang, Y. Zhang, W. Zhang, F. Yang, Eur. J. Med. 
Chem. 2016, 123, 354-364. 
[24] J. Qi, Y. Gou, Y. Zhang, K. Yang, S. Chen, L. Liu, X. Wu, T. Wang, W. Zhang, F. 
Yang, J. Med. Chem. 2016, 59, 7497‒7511. 
29 
 
                                                                                                                                                                                           
[25] A. Popovic-Bijelic, C. R. Kowol, M. E. S. Lind, J. Luo, F. Himo, E. A. Enyedy, V. B. 
Arion, A, Gräslund, J. Inorg. Biochem. 2011, 105, 1422-1431. 
[26] J. M. Phang, W. Liu, C. N. Hancock, J. W. Fisher, Curr. Opin. Clin. Nutr. Metab. 
Care, 2015, 18, 71-77. 
[27] O. J. Patino, L. E. Cuca, Phytochem. Lett. 2011, 4, 22-25. 
[28] A. Dobrova, S. Platzer, F. Bacher, M. N. M. Milunovic, A Dobrov, G. Spengler, E. A. 
Enyedy, G. Novitchi, V. B. Arion, Dalton Trans. 2016, 45, 13427-13439. 
[29] A. W. Addison, T. N. Rao, J. Reedijk, J. van Rijn, G. C, J. Chem. Soc. Dalton 
Trans. 1984, 1349-1356. 
[30] D. Carmona, M. P. Lamata, F. Viguri, I. Dobrinovich, F. L. Lahoz, L. A. Oro, Adv. 
Synth. Catal. 2002, 344, 499‒502. 
[31] E. A. Enyedy, M. F. Primik, C. R. Kowol, V. B. Arion, T. Kiss, B. K. Keppler, Dalton 
Trans. 2011, 40, 5895-5905. 
[32] O. Kahn, Molecular Magnetism, VCH Publishers, Inc., New York, Weinheim,  
Cambridge, 1993. 
[33] D. Gatteschi, R. Sessoli and J. Villain, Molecular Nanomagnets, Oxford University 
Press, Oxford, 2006. 
[34] V. V. Pavlishchuk, A. W. Addison, Inorg. Chim. Acta 2000, 298, 97-102. 
[35] D. R. Richardson, P. C. Sharpe, D. B. Lovejoy, D. Senaratne, D. S. Kalinowski, M. 
Islam, P. V. Bernhardt, J. Med. Chem. 2006, 49, 6510-6521.  
[36] D. S. Kalinowski, P. C. Sharpe, P. V. Bernhardt, D. R. Richardson, J. Med. Chem. 
2007, 50, 6212-6225. 
[37] F. Bacher, O. Domotor, M. Kaltenbrunner, M. Mojovic, A. Popovic-Bijelic, A. 
Graslund, A. Ozarowski, L. Filipovic, S. Radulovic, E. A. Enyedy, V. B. Arion, Inorg. 
Chem. 2014, 53, 12595-12609.  
[38] A. Basu, G. Das, Dalton Trans. 2011, 40, 2837-2843. 
[39] G. M. Sheldrick, Acta Crystallogr.,Sect. A: Fundam. Crystallogr. 2008, 64, 112-122. 
[40] STOE & Cie GmbH (2016). X-Area 1.76, software package for collecting single-
crystal data on STOE area-detector diffractometers, for image processing, scaling 
reflection intensities and for outlier rejection; Darmstadt, Germany 
30 
 
                                                                                                                                                                                           
[41] M. N. Burnett, G. K. Johnson. ORTEPIII, Report ORNL-5138; Oak Ridge National 
Laboratory: Oak Ridge, TN, 1996. 
[42] G. A. Bain, J. F. Berry, J. Chem. Educ. 2008, 85, 532‒536. 
[43] R. Supino, In Vitro Toxicity Testing Protocols, Springer, New York, 1995, 37-149. 
